Do analysts rate ORMP or CADL?

Candel Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 110.28%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Candel Therapeutics 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56

Is ORMP or CADL more profitable?

Oramed Pharmaceuticals' return on equity of -5.37% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.37% -4.83% Candel Therapeutics N/A -60.42% -41.33%

Does the media prefer ORMP or CADL?

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Candel Therapeutics. MarketBeat recorded 6 mentions for Oramed Pharmaceuticals and 2 mentions for Candel Therapeutics. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat Candel Therapeutics' score of 0.26 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend PRME or ORMP?

Prime Medicine presently has a consensus target price of $7.65, suggesting a potential upside of 175.18%. Given Prime Medicine's stronger consensus rating and higher possible upside, research analysts plainly believe Prime Medicine is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer PRME or ORMP?

In the previous week, Prime Medicine had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 7 mentions for Prime Medicine and 6 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat Prime Medicine's score of 0.60 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ACRS or ORMP?

Aclaris Therapeutics presently has a consensus price target of $11.50, suggesting a potential upside of 166.20%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aclaris Therapeutics is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.13 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer ACRS or ORMP?

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 6 mentions for Oramed Pharmaceuticals and 2 mentions for Aclaris Therapeutics. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat Aclaris Therapeutics' score of 0.97 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CABA or ORMP?

Cabaletta Bio presently has a consensus target price of $15.50, suggesting a potential upside of 414.95%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Cabaletta Bio is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CABA or ORMP more profitable?

Oramed Pharmaceuticals' return on equity of -5.37% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% Oramed Pharmaceuticals N/A -5.37% -4.83%

Does the media favor CABA or ORMP?

In the previous week, Cabaletta Bio had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 8 mentions for Cabaletta Bio and 6 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat Cabaletta Bio's score of 0.50 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DNA or ORMP?

Ginkgo Bioworks currently has a consensus price target of $8.50, suggesting a potential upside of 7.96%. Given Ginkgo Bioworks' higher possible upside, equities research analysts clearly believe Ginkgo Bioworks is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ginkgo Bioworks 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor DNA or ORMP?

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for Oramed Pharmaceuticals and 2 mentions for Ginkgo Bioworks. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat Ginkgo Bioworks' score of 0.55 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oramed Pharmaceuticals (ORMP) Competitors

$3.87 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.84 -0.03 (-0.78%)

As of 06/12/2026 05:02 PM Eastern

Compare

ORMP vs. CADL, PRME, ACRS, CABA, and DNA

Should you buy Oramed Pharmaceuticals stock or one of its competitors? MarketBeat compares Oramed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oramed Pharmaceuticals include Candel Therapeutics (CADL), Prime Medicine (PRME), Aclaris Therapeutics (ACRS), Cabaletta Bio (CABA), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry.

How does Oramed Pharmaceuticals compare to Candel Therapeutics?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Candel Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 110.28%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Oramed Pharmaceuticals' return on equity of -5.37% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%
Candel Therapeutics	N/A	-60.42%	-41.33%

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Candel Therapeutics. MarketBeat recorded 6 mentions for Oramed Pharmaceuticals and 2 mentions for Candel Therapeutics. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat Candel Therapeutics' score of 0.26 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oramed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Oramed Pharmaceuticals has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	$2M	79.20	$64.05M	$2.59	1.49
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Oramed Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, suggesting that its stock price is 149% less volatile than the broader market.

Summary

Oramed Pharmaceuticals beats Candel Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Oramed Pharmaceuticals has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	108.45	-$201.14M	-$1.23	N/A
Oramed Pharmaceuticals	$2M	79.20	$64.05M	$2.59	1.49

In the previous week, Prime Medicine had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 7 mentions for Prime Medicine and 6 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat Prime Medicine's score of 0.60 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oramed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Oramed Pharmaceuticals' return on equity of -5.37% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Prime Medicine presently has a consensus target price of $7.65, suggesting a potential upside of 175.18%. Given Prime Medicine's stronger consensus rating and higher possible upside, research analysts plainly believe Prime Medicine is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Prime Medicine beats Oramed Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Aclaris Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oramed Pharmaceuticals has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	77.05	-$64.92M	-$0.56	N/A
Oramed Pharmaceuticals	$2M	79.20	$64.05M	$2.59	1.49

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 6 mentions for Oramed Pharmaceuticals and 2 mentions for Aclaris Therapeutics. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat Aclaris Therapeutics' score of 0.97 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oramed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclaris Therapeutics presently has a consensus price target of $11.50, suggesting a potential upside of 166.20%. Given Aclaris Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aclaris Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oramed Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Oramed Pharmaceuticals' return on equity of -5.37% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

Summary

Oramed Pharmaceuticals beats Aclaris Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Oramed Pharmaceuticals has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Oramed Pharmaceuticals	$2M	79.20	$64.05M	$2.59	1.49

Cabaletta Bio has a beta of 3.21, indicating that its stock price is 221% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Cabaletta Bio presently has a consensus target price of $15.50, suggesting a potential upside of 414.95%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Cabaletta Bio is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cabaletta Bio had 2 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 8 mentions for Cabaletta Bio and 6 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat Cabaletta Bio's score of 0.50 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oramed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals' return on equity of -5.37% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

Summary

Oramed Pharmaceuticals beats Cabaletta Bio on 9 of the 14 factors compared between the two stocks.

How does Oramed Pharmaceuticals compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Ginkgo Bioworks has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for Oramed Pharmaceuticals and 2 mentions for Ginkgo Bioworks. Oramed Pharmaceuticals' average media sentiment score of 1.18 beat Ginkgo Bioworks' score of 0.55 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oramed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Oramed Pharmaceuticals' return on equity of -5.37% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

Ginkgo Bioworks currently has a consensus price target of $8.50, suggesting a potential upside of 7.96%. Given Ginkgo Bioworks' higher possible upside, equities research analysts clearly believe Ginkgo Bioworks is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oramed Pharmaceuticals has lower revenue, but higher earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.02	-$312.76M	-$5.36	N/A
Oramed Pharmaceuticals	$2M	79.20	$64.05M	$2.59	1.49

Summary

Oramed Pharmaceuticals beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks.

Get Oramed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORMP vs. The Competition

Export

Metric	Oramed Pharmaceuticals	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$158.40M	$8.39B	$6.74B	$12.07B
Dividend Yield	6.46%	2.50%	2.67%	5.67%
P/E Ratio	1.49	15.64	24.21	24.42
Price / Sales	79.20	7.06	512.04	109.94
Price / Cash	42.66	17.44	27.48	37.92
Price / Book	0.77	3.62	10.66	6.83
Net Income	$64.05M	$224.06M	$3.57B	$337.67M
7 Day Performance	6.32%	-1.40%	0.58%	1.17%
1 Month Performance	-16.59%	4.39%	1.54%	3.16%
1 Year Performance	81.69%	-0.88%	25.40%	30.58%

Oramed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORMP Oramed Pharmaceuticals	2.2869 of 5 stars	$3.87 flat	N/A	+81.7%	$158.40M	$2M	1.49	10	Positive News Analyst Upgrade Analyst Revision
CADL Candel Therapeutics	2.4967 of 5 stars	$8.42 -1.1%	$18.00 +113.8%	+66.9%	$623.53M	N/A	N/A	60
PRME Prime Medicine	2.2144 of 5 stars	$3.21 -5.6%	$7.65 +138.3%	N/A	$614.10M	$4.63M	N/A	N/A	News Coverage Gap Down
ACRS Aclaris Therapeutics	3.0984 of 5 stars	$4.63 +6.7%	$11.50 +148.4%	+193.9%	$606.14M	$7.83M	N/A	100	Positive News
CABA Cabaletta Bio	2.8925 of 5 stars	$3.68 +0.3%	$15.50 +321.2%	+51.3%	$598.41M	N/A	N/A	50	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORMP) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. CADL, PRME, ACRS, CABA, and DNA

How does Oramed Pharmaceuticals compare to Candel Therapeutics?

Summary

How does Oramed Pharmaceuticals compare to Prime Medicine?

Summary

How does Oramed Pharmaceuticals compare to Aclaris Therapeutics?

Summary

How does Oramed Pharmaceuticals compare to Cabaletta Bio?

Summary

How does Oramed Pharmaceuticals compare to Ginkgo Bioworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oramed Pharmaceuticals (ORMP) Competitors

ORMP vs. CADL, PRME, ACRS, CABA, and DNA

How does Oramed Pharmaceuticals compare to Candel Therapeutics?

Do insiders and institutionals hold more shares of ORMP or CADL?

Do analysts rate ORMP or CADL?

Is ORMP or CADL more profitable?

Does the media prefer ORMP or CADL?

Which has higher valuation and earnings, ORMP or CADL?

Which has more risk and volatility, ORMP or CADL?

Summary

How does Oramed Pharmaceuticals compare to Prime Medicine?

Which has stronger valuation and earnings, PRME or ORMP?

Does the media prefer PRME or ORMP?

Is PRME or ORMP more profitable?

Do insiders & institutionals hold more shares of PRME or ORMP?

Which has more volatility & risk, PRME or ORMP?

Do analysts recommend PRME or ORMP?

Summary

How does Oramed Pharmaceuticals compare to Aclaris Therapeutics?

Which has more volatility & risk, ACRS or ORMP?

Do institutionals and insiders hold more shares of ACRS or ORMP?

Which has better valuation & earnings, ACRS or ORMP?

Does the media prefer ACRS or ORMP?

Do analysts rate ACRS or ORMP?

Is ACRS or ORMP more profitable?

Summary

How does Oramed Pharmaceuticals compare to Cabaletta Bio?

Which has preferable valuation & earnings, CABA or ORMP?

Which has more risk & volatility, CABA or ORMP?

Do analysts recommend CABA or ORMP?

Do institutionals & insiders hold more shares of CABA or ORMP?

Does the media favor CABA or ORMP?

Is CABA or ORMP more profitable?

Summary

How does Oramed Pharmaceuticals compare to Ginkgo Bioworks?

Which has more volatility & risk, DNA or ORMP?

Do insiders & institutionals hold more shares of DNA or ORMP?

Does the media favor DNA or ORMP?

Is DNA or ORMP more profitable?

Do analysts prefer DNA or ORMP?

Which has stronger earnings and valuation, DNA or ORMP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORMP vs. The Competition

Oramed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools